DURECT ANNOUNCES RESULTS FROM COHORT 2 OF ITS ON-GOING PHASE II STUDY

Durect has announced positive preliminary results from the second cohort of an on-going Phase II clinical study in hernia patients for Durect's postoperative pain relief depot product candidate, SABER-Bupivacaine.

SABER-Bupivacaine is based on Durect's patented SABER delivery technology and is administered around the surgical site after surgery to provide three days or more of regional pain relief.

"The preliminary findings from our Phase II study are very significant for the SABER-Bupivacaine development program and Durect in that they are supportive thus far of all our established clinical objectives for this product candidate of safety, a drug delivery duration of three days or more, and in comparison to the current standard of care, improved pain relief and reduction in the use of supplemental analgesic medication. Of note, five of the ten patients receiving SABER-Bupivacaine in cohort 2 of our Phase II study took no supplemental analgesics over the four-day period following treatment," stated James Brown, president and CEO of Durect.